Prosecution Insights
Last updated: November 04, 2026
Application No. 18/524,594

DETECTION METHOD

Final Rejection §102§DOUBLEPATENT
Filed
Nov 30, 2023
Priority
Jun 01, 2018 — provisional 62/679,621 +4 more
Examiner
GODDARD, LAURA B
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Geneoscopy Inc.
OA Round
2 (Final)
51%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
64%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
657 granted / 1289 resolved
-9.0% vs TC avg
Moderate +13% lift
Without
With
+13.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
61 currently pending
Career history
1359
Total Applications
across all art units

Statute-Specific Performance

§101
7.8%
-32.2% vs TC avg
§103
28.6%
-11.4% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
26.8%
-13.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1289 resolved cases

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 1. Claims 51-72 are pending and being examined. Specification 2. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. Examiner suggests amending the title to relate to the claimed invention of evaluating eukaryotic cells in stool samples. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 3. Claim(s) 51-59, 62-66, and 69-72 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Spethmann et al (International Journal of Molecular Medicine, 2004, 13:451-454). Spethmann teaches a method for evaluating a stool sample, the method comprising: a) collecting a stool sample and immediately freezing them at -70ºC in the absence of buffer and surfactant, and b) in a laboratory, analyzing eukaryotic cells in the stool sample by: i) thawing an aliquot of the stool sample and making a suspension of the aliquot in Puck’s Saline G (= Puck’s balanced salt solution, that functions as an aqueous and osmotic balance buffer to preserve cells in samples including the proteins and nucleic acid they contain); ii) isolating and analyzing the eukaryotic cells by contacting the sample with magnetic microbeads carrying a monoclonal antibody that binds EpCam protein, a human marker of epithelial cells, thereby analyzing for the presence of protein biomarker; iii) extracting DNA from the cells and analyzing the DNA for p53 gene; iv) extracting RNA and analyzing the RNA for CK18 biomarker (Materials and methods p. 451-452; Figures 1-2; Results p. 452-453). 4. Claim(s) 51, 52, 62-70, and 72 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Heigh et al (PLOS ONE, 2014, 9:e85659, pages 1-6). Heigh teaches a method a method for evaluating a stool sample, the method comprising: a) collecting a fresh stool sample that is inherently not present in a buffer or surfactant; b) placing the stool sample into a suspension of preservative solution; and c) in a laboratory, analyzing eukaryotic cells in the stool sample by: i) conducting a commercially available fecal immunochemical test (FIT) analysis that tests for the presence of hemoglobin (a protein present in eukaryotic red blood cells); and ii) assaying for DNA markers methylated BMP3, NDRG4, mutant KRAS, β-actin, and hemoglobin derived from exfoliated cells in the sample (p. 2; Figure 2). 5. Claim(s) 51-66, and 72 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US Patent Application Publication 2011/0129860, Karl et al, published 2011; as evidenced by Spethmann et al (International Journal of Molecular Medicine, 2004, 13:451-454). Karl teaches stool samples have been in contact with intestinal or even cancerous cells ([17]) and are a source of analytes to assess the presence of colorectal cancer ([31-39]; [47]; claims 1-2). Karl teaches a method a method for evaluating a stool sample, the method comprising: a) collecting a fresh stool sample that is inherently not present in a buffer or surfactant ([81]); and b) in a laboratory, analyzing the stool sample by: i) making a suspension of the stool sample in a diluent ([63]; [81]), wherein the diluent comprises: a buffer, protease inhibitors that preserve proteins, a surfactant/detergent (= analyte-releasing agent that lyses the cells in the stool sample), and/or a chaotropic reagent ([64-76]); wherein the buffer comprises phosphate-buffered saline (PBS) which is aqueous and an osmotic balancer ([65]); wherein the detergent is a non-ionic surfactant ([76]); and wherein the chaotropic reagent is guanidinium-hydrochloride, which is inherently a ribonuclease inhibitor that preserves RNA ([76]); and ii) analyzing proteins in the sample by immunoassay, including hemoglobin/haptoglobin and calprotectin biomarkers (abstract; [63]; [82-90]; claim 1; Examples 1-3), and assaying for additional cancer biomarkers including CEA, CYFRA 21-2, CA19-9, CA 72-4, NNMT, PROC, and SAHH ([48-62]; claim 2; Example 3). As evidenced by Spethmann, stool samples inherently have exfoliated eukaryotic cells present (abstract; Introduction), which is noted by Karl ([17]), therefore the method of Karl analyzing stool samples inherently analyzes eukaryotic cells and their proteins present in the stool samples. 6. Claim(s) 51-72 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by US Patent 11,479,820, Barnell et al, claiming priority to 2017. The applied reference has a common Applicant with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Barnell teaches a method for evaluating a stool sample, the method comprising: a) collecting a fresh stool sample that is inherently not present in a buffer or surfactant; b) in a laboratory, isolating eukaryotic cells from the stool sample by: i) mixing the stool sample with a buffer, a surfactant and a ribonuclease inhibitor to form a suspension; ii) separating the suspension into a portion enriched for eukaryotic cells and a portion enriched for bacterial cells and retaining the portion enriched for eukaryotic cells; iii) adding a chaotropic agent and optionally a surfactant to the portion enriched for eukaryotic cells to form a lysate; iv) isolating RNA, DNA, and proteins; and c) analyzing the RNA, DNA, and proteins for multiple biomarkers (claims 1-20; col. 4, line 62 to col. 9, line 51; Examples); wherein the buffer is Hanks balanced salt solution, Alsever's solution, Earle's balanced salt solution, Gey's balanced salt solution, Phosphate buffered saline, Puck's balanced salt solution, Ringer's balanced salt solution, Simm's balanced salt solution, TRIS-buffered saline, or Tyrode's balanced salt solution (col. 8, lines 1-10); wherein the surfactant is ionic or non-ionic (col. 8, lines 10-11); wherein the stool sample can be suspended in the presence or absence of surfactant (col. 8, lines 25-33); the method further comprising testing for the presence of blood using a fecal immunochemical test (FIT) (col. 19, lines 4-21; col. 21, lines 14-35). 7. Claim(s) 51-72 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by US Patent Application Publication 2023/0203591, Barnell et al, claiming priority to 2017 (Application No. 17/887,752). The applied reference has a common Applicant with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. US Patent Application Publication 2023/0203591, Barnell claims priority to US Patent 11,479,820, Barnell cited above, and comprises the same disclosure as US Patent 11,479,820, therefore, US Patent Application Publication 2023/0203591 anticipates the instant claims for the same reasons stated above for US Patent 11,479,820. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 8. Claims 51-57, 59-66, 69-71 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. US Patent 11,479,820. Claim 56 is rejected further in view of Spethmann et al (International Journal of Molecular Medicine, 2004, 13:451-454). Although the claims at issue are not identical, they are not patentably distinct from each other because the US Patent claims a method comprising steps and reagents overlapping with, and rendering obvious, the instant method of analyzing eukaryotic cells from a collected stool sample. The US Patent claims: 1. A method of isolating eukaryotic nucleic acid from a stool sample, the method comprising: a) mixing the sample with a buffer, a surfactant and a ribonuclease inhibitor to form a suspension; b) separating the suspension into a portion enriched for eukaryotic cells and a portion enriched for bacterial cells and retaining the portion enriched for eukaryotic cells; c) adding a chaotropic agent and optionally a surfactant to the portion enriched for eukaryotic cells to form a lysate; d) fractioning the lysate into a cell debris layer, a layer comprising eukaryotic nucleic acids and a lipid layer; and e) collecting the layer comprising eukaryotic nucleic acids and optionally the lipid layer. 2. The method of claim 1, further comprising providing a stool sample. 3. The method of claim 1, wherein the stool sample is a human stool sample. 4. The method of claim 1, wherein the separating step comprises centrifugation or a column-based method. 5. The method of claim 1, wherein the separating step utilizes targeted probes that bind eukaryotic cells. 6. The method of claim 1, wherein the separating step utilizes differential filtration. 7. The method of claim 1, wherein i) step a) is repeated one, two, three, four or more times, ii) step b) is repeated one, two, three, four or more times, or iii) both step a) and step b) are repeated one, two, three, four or more times. 8. The method of claim 1, wherein the fractionating step comprises centrifugation or differential filtration. 9. The method of claim 1, wherein the fractionating step utilizes targeted probes that specifically bind eukaryotic nucleic acid. 10. The method of claim 1, wherein i) step d) is repeated two or more times, ii) step e) is repeated two or more times, or iii) both step d) and step e) are repeated two or more times. 11. The method of claim 1, further comprising extracting the eukaryotic nucleic acids from the collected layer comprising eukaryotic nucleic acids. 12. The method of claim 1, wherein the extraction method is a magnetic particle-based, column-based, filter-based, bead-based, or organic solvent-based method. 13. The method of claim 1, wherein the nucleic acid comprises DNA, RNA, total RNA, mRNA, tRNA, rRNA, ncRNA, smRNA, or snoRNA, or a combination of any of DNA, RNA, total RNA, mRNA, tRNA, rRNA, ncRNA, smRNA, or snoRNA. 14. The method of claim 1, wherein the separating step comprises centrifugation. 15. The method of claim 1, wherein the extraction method comprises a magnetic particle-based method. 16. The method of claim 1, wherein the nucleic acid comprises RNA. 17. The method of claim 1, wherein the nucleic acid comprises mRNA. 18. The method of claim 1, further comprising a step of analyzing the extracted nucleic acid via microarray sequencing, molecular barcoding, probe capture, polymerase chain reaction (PCR), ddPCR, RT-PCR, RT-qPCR, or nucleic acid sequencing. 19. The method of claim 1, further comprising a step of analyzing the extracted nucleic acid via ddPCR. 20. The method of claim 1, further comprising a step of analyzing the extracted nucleic acid via PCR. The initial stool sample used in the method requires collection and inherently would not be present in a buffer or surfactant when obtained. With regard to claim 56, the US Patent does not specify the buffer used to suspend the stool sample, in order to isolate the eukaryotic cells for nucleic acid analysis. Spethmann teaches successfully suspending stool samples in buffer Puck’s Saline G (Puck’s balanced salt solution, that functions as an aqueous and osmotic balance buffer) in order to isolate the eukaryotic cells for nucleic acid analysis. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to utilize Puck’s balanced salt solution as the buffer in the method of the US Patent. One would have been motivated to, and have a reasonable expectation of success to, given the US Patent claims suspending the stool sample in a buffer for purposes of isolating eukaryotic cells for nucleic acid analysis, and Spethmann demonstrates successfully using Puck’s balanced salt solution as a buffer for that same function. 9. Claim 51-57, 59-66, 69-71 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 38-57 of copending Application No. 17/887,752 (reference application). Claim 56 is rejected further in view of Spethmann et al (International Journal of Molecular Medicine, 2004, 13:451-454). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending application claims a method comprising steps and reagents overlapping with, and rendering obvious, the instant method of analyzing eukaryotic cells from a collected stool sample. The copending application claims: 1. A method of isolating eukaryotic nucleic acid from a stool sample, the method comprising: a) mixing the sample with a buffer, a surfactant and a ribonuclease inhibitor to form a suspension; b) separating the suspension into a portion enriched for eukaryotic cells and a portion enriched for bacterial cells and retaining the portion enriched for eukaryotic cells; c) adding a chaotropic agent and optionally a surfactant to the portion enriched for eukaryotic cells to form a lysate; d) fractioning the lysate into a cell debris layer, a layer comprising eukaryotic nucleic acids and a lipid layer; and e) collecting the layer comprising eukaryotic nucleic acids and optionally the lipid layer. 2. The method of claim 1, further comprising providing a stool sample. 3. The method of claim 1, wherein the stool sample is a human stool sample. 4. The method of claim 1, wherein the stool sample is a non-human animal stool sample. 5. The method of claim 4, wherein the non-human animal is selected from the group consisting of dog, cat, non-human primate, ruminant, ursid, equid, pig, sheep, goat, camelid, buffalo, deer, elk, moose, mustelid, rabbit, guinea pig, hamster, rat, mouse, pachyderm, rhinoceros, and chinchilla. 6. The method of claim 5, wherein the non-human animal is a dog. 7. The method of claim 5, wherein the non-human animal is a cat. 8. The method of claim 1, wherein the separating step comprises centrifugation. 9. The method of claim 1, wherein the separating step comprises a column based method. 10. The method of claim 1, wherein the separating step utilizes targeted probes that bind eukaryotic cells. 11. The method of claim 1, wherein the separating step utilizes differential filtration. 12. The method of claim 1, wherein steps a and b are repeated one, two, three, four or more times. 13.The method of claim 1, wherein the fractionating step comprises centrifugation. 14. The method of claim 1, wherein the fractionating step utilizes targeted probes that specifically bind eukaryotic nucleic acid. 15. The method of claim 1, wherein the fractionating step utilizes differential filtration. 16. The method of claim 1, wherein steps di and e are repeated two or more times. 17. The method of claim 1, wherein the layer comprising eukaryotic nucleic acids is collected using a small-bore tip. 18. The method of claim 1, further comprising extracting the eukaryotic nucleic acids from the collected layer comprising eukaryotic nucleic acids. 19. The method of claim 1, wherein the extraction method is a magnetic particle-based, column based, filter-based, bead-based, or organic solvent-based method. 20. The method of claim 1, wherein the nucleic acid comprises DNA, RNA, total RNA, mRNA, tRNA, rRNA, ncRNA, smRNA, or sno RNA, or a combination of any of DNA, RNA, total RNA, mRNA, tRNA, rRNA, ncRNA, smRNA, or sno RNA. 21. A method of detecting a eukaryotic biomarker in a stool sample, the method comprising: analyzing the extracted nucleic acid of claim 1 by microarray sequencing, molecular barcoding, probe capture, polymerase chain reaction (PCR), ddPCR, RT-PCR, RT-qPCR, or nucleic acid sequencing. 22. The method of claim 21, wherein the eukaryotic biomarker is selected from the biomarkers listed in Figure 6 (Panel A) or Figure 13 (Panel B). 23. The method of claim 21, wherein the eukaryotic biomarker is a B cell marker, a T cell marker, or an immunoglobulin. 24. A method of determining whether a subject is at risk for colorectal cancer, the method comprising: a) measuring the level of expression of two or more colorectal neoplasm biomarker genes selected from any of the colorectal neoplasm biomarker genes listed in Figure 6 (Panel A) or Figure 13 (Panel B) in a biological sample from the subject; b) comparing the measured expression level of the two or more colorectal neoplasm biomarker genes in the biological sample with the measured expression level of the two or more colorectal neoplasm biomarker genes in a control, wherein a difference in the measured expression level of the two or more genes in the biological sample relative to the measured expression level of the two or more genes in the control indicates that the subject is at risk for colorectal cancer. 25. The method of claim 24, wherein the biological sample comprises a human nucleic acid isolated according to the method set forth in claims 1-20. 26. The method of claim 24, wherein the colorectal neoplasm biomarker genes contained within the 200 differentially expressed transcript clusters shown in Figure 5A and contained within the common pathways associated with the colorectal cancer shown in Figure 5B. 27. The method of claim 24, wherein the colorectal neoplasm biomarker gene is selected from the biomarkers listed in Figure 6 (Panel A) or Figure 13 (Panel B). 28. A method of selecting a clinical plan for a subject having or at risk for colorectal cancer, the method comprising: a) measuring the level of expression of two or more colorectal neoplasm biomarker genes selected from any of the colorectal neoplasm biomarker genes listed in Figure 6 (Panel A) or Figure 13 (Panel B) in a biological sample from the subject; b) comparing the measured expression level of the two or more colorectal neoplasm biomarker genes in the biological sample with the measured expression level of the two or more colorectal neoplasm biomarker genes in a control, wherein a difference in the measured expression level of the two or more genes in the biological sample relative to the measured expression level of the two or more genes in the control indicates that the subject has or is at risk for colorectal cancer; and c) selecting a clinical plan based on step b. 29. The method of claim 28, wherein the biological sample comprises a human nucleic acid isolated according to the method set forth in claims 1-20. 30. The method of claim 28, wherein the colorectal neoplasm biomarker genes contained within the 200 differentially expressed transcript clusters shown in Figure 5A and contained within the common pathways associated with the colorectal cancer shown in Figure 5B. 31. The method of claim 28, wherein the colorectal neoplasm biomarker gene is selected from the biomarkers listed in Figure 6 (Panel A) or Figure 13 (Panel B). 32. A method of determining whether a non-human animal is at risk for a gastrointestinal disorder, the method comprising: a) measuring the level of expression of one or more B cell, T cell, or immunoglobulin genes in a biological sample from the subject; b) comparing the measured expression level of the one or more B cell, T cell, or immunoglobulin genes in the sample with the measured expression level of one or more B cell, T cell, or immunoglobulin genes in a control, wherein a difference in the measured expression level of the one or more genes in the biological sample relative to the measured expression level of the one or more genes in the control indicates that the subject is at risk for a gastrointestinal disorder. 33. The method of claim 32, wherein the biological sample comprises a non-human animal nucleic acid isolated according to the method set forth in claims 1-20. 34. The method of claim 32, wherein the gastrointestinal disorder comprises gastrointestinal lymphoma or inflammatory bowel disease. 35. The method of claim 32, wherein the non-human animal is a cat. 36. The method of claim 32, wherein the non-human animal is a dog. 37. The method of claim 32, wherein the biological sample comprises a stool sample. The initial stool sample used in the method requires collection and inherently would not be present in a buffer or surfactant when obtained. With regard to claim 56, the copending application does not specify the buffer used to suspend the stool sample, in order to isolate the eukaryotic cells for nucleic acid analysis. Spethmann teaches successfully suspending stool samples in buffer Puck’s Saline G (Puck’s balanced salt solution, that functions as an aqueous and osmotic balance buffer) in order to isolate the eukaryotic cells for nucleic acid analysis. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to utilize Puck’s balanced salt solution as the buffer in the method of the copending application. One would have been motivated to, and have a reasonable expectation of success to, given the copending application claims suspending the stool sample in a buffer for purposes of isolating eukaryotic cells for nucleic acid analysis, and Spethmann demonstrates successfully using Puck’s balanced salt solution as a buffer for that same function. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. 10. Conclusion: No claim is allowed. 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAURA B GODDARD whose telephone number is (571)272-8788. The examiner can normally be reached Mon-Fri, 7am-3:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at 571-270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Laura B Goddard/ Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Nov 30, 2023
Application Filed
Jun 05, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT
Sep 03, 2026
Response Filed
Nov 03, 2026
Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782364
METHODS AND KITS FOR DETECTING LIVER DYSFUNCTION IN A SUBJECT
5y 5m to grant Granted Nov 03, 2026
Patent 12780942
ARTC1 LIGANDS FOR CANCER TREATMENT
4y 0m to grant Granted Nov 03, 2026
Patent 12780946
ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF
2y 10m to grant Granted Nov 03, 2026
Patent 12774334
MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
3y 4m to grant Granted Oct 27, 2026
Patent 12753450
CORONAVIRUS DETECTION
4y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
51%
Grant Probability
64%
With Interview (+13.4%)
3y 2m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1289 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month